Clinical Report: Impact of Metabolic Comorbidities on Survival Outcomes in HBV-HCC

Overview

This study investigates the impact of metabolic comorbidities on overall survival in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC).

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, particularly in regions with high hepatitis B virus (HBV) prevalence, such as China. Understanding the influence of metabolic comorbidities on HCC prognosis is crucial, as these conditions may exacerbate disease progression and affect treatment outcomes. This study aims to clarify the relationship between metabolic comorbidities and survival in patients with HBV-related HCC.

Data Highlights

Key Findings

• Metabolic comorbidities were associated with poorer overall survival in HBV-related HCC patients.
• Type 2 diabetes mellitus (T2DM) was identified as an independent risk factor for overall survival.
• The presence of hypertension and low HDL levels also contributed to worse survival outcomes.
• Patients with all three metabolic comorbidities had significantly worse overall survival (p=0.043).
• Propensity score matching was utilized to ensure comparability between groups.

Clinical Implications

Clinicians should consider the presence of metabolic comorbidities when assessing prognosis in patients with HBV-related HCC.

Conclusion

The study indicates that metabolic comorbidities are associated with survival in patients with HBV-related HCC.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Impact of Metabolic Comorbidities on Survival Outcomes in HBV-HCC
2. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) - PMC
3. Frontiers in Oncology — Establishment of prognostic nomogram in cervical cancer with hepatitis B virus infection: a retrospective study
4. Journal of Gastrointestinal Surgery — Hepatocellular Carcinoma in Pediatric and Adolescent Populations: Clinical Features and Management Strategies
5. Frontiers in Oncology — Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study
6. Journal of Gastrointestinal Surgery — Influence of Type 2 Diabetes on Cancer Outcomes in Hepatocellular Carcinoma Among Patients with Non-Cirrhotic Non-Alcoholic Steatohepatitis: A Matched-Pair Study
7. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) - PMC
8. Diagnosing and defining MASLD in people living with chronic hepatitis B | Communications Medicine
9. Frontiers | Metabolic comorbidities affect the survival of hepatitis B virus-related hepatocellular carcinoma in Chinese patients: A retrospective cohort study with propensity score matching